TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00855894

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pertuzumab
Description: After a single administration of a loading dose of 840 mg IV, patients received a maintenance dose of 420 mg IV every 3 weeks (q3w).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: Patients received 150 mg orally once a day which was reduced to 100 mg orally once a day in a protocol amendment dated 19 May 2010.
Study: NCT02913118

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Andrographolid Sulfonate Injection (AS Injection)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cephalosporin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cephalosporin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Azithromycin, Minocycline or Doxycycline

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin, Minocycline or Doxycycline

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Amoxicillin-clavulantic acid
Study: NCT01520766

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: prefabricated titanium post
Description: posts: diameter of 1.4 mm; length of 13 mm adhesively luted within the root canal using self-adhesive resin cement and direct composite cores using an etch-and-rinse adhesive were built up crown preparation was performed, while the finishing line for the final restoration was set at least 2 mm apical the composite build-up in dentin to ensure a proper dentin ferrule design

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: prefabricated glass fiber reinforced composite post
Description: posts: diameter of 1.4 mm; length of 13 mm adhesively luted within the root canal using self-adhesive resin cement and direct composite cores using an etch-and-rinse adhesive were built up crown preparation was performed, while the finishing line for the final restoration was set at least 2 mm apical the composite build-up in dentin to ensure a proper dentin ferrule design
Study: NCT00533884

Intervention type: OTHER
Intervention: Assessment of therapy complications
Description: Assessment of neurocognitive function, functional status, symptom prevalence and distress, and mood alterations

Intervention type: OTHER
Intervention: Neurocognitive assessment
Description: Assessment of neurocognitive domains: attention/concentration, executive function, verbal learning, verbal memory, verbal fluency

Intervention type: OTHER
Intervention: Quality-of-life assessment
Description: Assessment of quality of life using Cantrill's Ladder at baseline and 3 months post-treatment
Study: NCT01246986

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2157299
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2157299
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2157299
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2157299
Description: Administered orally
Study: NCT01040104

Intervention type: OTHER
Intervention: Blood taking
Description: Blood taking on day 0
Study: NCT01246986

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2157299
Description: Administered orally
Study: NCT02913118

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin-clavulantic acid

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fluoroquinolones
Study: NCT02843698

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Normal saline
Study: NCT02164578

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Study: NCT02913118

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluoroquinolones

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00780377

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bradykinin
Description: Bradykinin 0, 0.2, 0.6, 2.0 ug/min intracoronary, for 5 minutes at each dose.
Study: NCT00776035

Intervention type: PROCEDURE
Intervention: PET (Positron Emission Tomography)
Description: This is a diagnostic scan that requires the injection of radioactive tracer compounds intravenously using an IV placed in the arm.

Intervention type: PROCEDURE
Intervention: PET (Positron Emission Tomography)
Description: This is a diagnostic scan that requires the injection of radioactive tracer compounds intravenously using an IV placed in the arm.

Intervention type: PROCEDURE
Intervention: Echocardiogram
Description: An echocardiogram is an ultrasound of the heart. Participants received a complete 2D- and Doppler echocardiographic examination on the day of the PET scan.

Intervention type: PROCEDURE
Intervention: Echocardiogram
Description: An echocardiogram is an ultrasound of the heart. Participants received a complete 2D- and Doppler echocardiographic examination on the day of the PET scan.

Intervention type: RADIATION
Intervention: ^15O-water
Description: This is a radioactive tracer used to study blood flow in the heart during the PET scan. It was administered intravenously at a dose of 20 mCi.

Intervention type: RADIATION
Intervention: ^15O-water
Description: This is a radioactive tracer used to study blood flow in the heart during the PET scan. It was administered intravenously at a dose of 20 mCi.

Intervention type: RADIATION
Intervention: 1-^11C-palmitate
Description: This is a radioactive tracer used to study fatty acid usage in the heart during the PET scan. It was administered intravenously at a dose of 20 mCi.

Intervention type: RADIATION
Intervention: 1-^11C-palmitate
Description: This is a radioactive tracer used to study fatty acid usage in the heart during the PET scan. It was administered intravenously at a dose of 20 mCi.

Intervention type: RADIATION
Intervention: 1-^11C-glucose
Description: This is a radioactive tracer used to study glucose usage in the heart during the PET scan. It was administered intravenously at a dose of 20 Mci..
Study: NCT02164578

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Study: NCT03521076

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Reality
Description: Participants will have the opportunity to choose a game or relaxation experience to utilize during a botulinum toxin injection to distract from pain and anxiety during one visit. Virtual Reality will not be available during the other visit. AppliedVR has a number of games and relaxation experiences available for participants to chose from.
Study: NCT00776035

Intervention type: RADIATION
Intervention: 1-^11C-glucose
Description: This is a radioactive tracer used to study glucose usage in the heart during the PET scan. It was administered intravenously at a dose of 20 Mci..
Study: NCT01901458

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Spectra Optia® IDL-Set
Description: Peripheral blood progenitor cell apheresis in G-CSF mobilized allogeneic donors using the Spectra Optia® cell separator

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Spectra Optia® Collection Set
Description: Peripheral blood progenitor cell apheresis in G-CSF mobilized allogeneic donors using the Spectra Optia® cell separator
Study: NCT03662802

Intervention type: OTHER
Intervention: Neural Network Classifier
Description: The convolutional neural network is configured to receive an electrocardiogram segment as an input and to generate an output indicative of whether the received electrocardiogram segment represents a cardiac arrhythmia. No specific features of the electrocardiogram are identified to the convolutional neural network, and the received electrocardiogram segment is not filtered, transformed, or processed prior to reception by the algorithm. The algorithm is trained in a similar manner - the electrocardiogram segments are the sole input to the convolutional neural network.
Study: NCT03045211

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dynamic Standing Table
Description: The dynamic standing table is a height-adjustable standing table which gives periodic cues to the user to make stepping movements.
Study: NCT04033354

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HLX10
Description: HLX10 is an innovative monoclonal antibody targeting PD-1，developed by Shanghai Henlius Biotech, Inc.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin and nab paclitaxel
Description: chemotherapeutics

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: carboplatin and nab paclitaxel
Description: chemotherapeutics

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT02094274

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LAS40468

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Salmeterol/fluticasone propionate
Study: NCT01246986

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2157299
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2157299
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramucirumab
Description: Administered IV
Study: NCT02094274

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01246986

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramucirumab
Description: Administered IV
Study: NCT04021238

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Perflutren lipid microsphere
Description: Baseline B-mode US will be performed to confirm the lesions being imaged (unless it is a subject with no lesions, then a basic B-mode US will be performed. Perflutren is a diagnostic drug that is intended to be used for contrast enhancement. The vial contains a clear, colorless, sterile, non-pyrogenic, hypertonic solution which is activated by mechanical agitation with Vialmix®.It will be dispensed in inactivated form to a study team member. The contrast agent will be activated just prior to administration (ideally to be used within 5 minutes of activation). Contrast agent Definity (or Lumason) will be activated according to package insert instructions, including use of VialMix®, the device used to activate Definity. Administration will occur IV in coordination with sonography staff trained specifically in contrast ultrasound imaging.The total imaging time is anticipated to be less than 30 minutes.
Study: NCT01040104

Intervention type: OTHER
Intervention: Blood taking
Description: Blood taking on day 0

Intervention type: OTHER
Intervention: Blood taking
Description: Blood taking on day 90
Study: NCT04021238

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulfur hexafluoride lipid microspheres
Description: Baseline B-mode US will be performed to confirm the lesions being imaged (unless it is a subject with no lesions, then a basic B-mode US will be performed. Lumason will be used as a secondary contrast agent only if Definity(perflutren) is unavailable.This drug will be administered using the dosing range and administration type within the Lumason prescribing information. The contrast agent will be activated just prior to administration (ideally to be used within 5 minutes of activation). Contrast agent Definity (or Lumason) will be activated according to package insert instructions, including use of VialMix®, the device used to activate Definity. Administration will occur IV in coordination with sonography staff trained specifically in contrast ultrasound imaging.The total imaging time is anticipated to be less than 30 minutes.
Study: NCT01387087

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP015K
Description: oral
Study: NCT03724916

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-079
Description: TAK-079 subcutaneous injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-079
Description: TAK-079 subcutaneous injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-079
Description: TAK-079 subcutaneous injection.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: TAK-079 Placebo
Description: TAK-079 placebo-matching subcutaneous injection.
Study: NCT01284816

Intervention type: PROCEDURE
Group type: OTHER
Intervention: bariatric surgery
Description: The bariatric surgery is a relevant treatment for severely obese patients those with metabolic complications, as it significantly reduces weight, hypertension and ameliorates glycemic control.
Study: NCT01897558

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pacemaker implantation

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pacemaker implantation
Study: NCT01834573

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: physical exercise
Description: 10 weeks physical exercise; three times a week
Study: NCT03666546

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lactulose crystals 20 g
Description: White or almost white crystalline powder. The product will be provided in sachets to be dissolved in 250 mL water.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lactulose crystals 30 g
Description: White or almost white crystalline powder. The products will be provided in sachets to be dissolved in 250 mL water.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lactulose liquid 20 g
Description: Clear, viscous liquid, colourless or pale brownish-yellow liquid syrup (solution). The products will be provided in sachets to be dissolved in 250 mL water.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lactulose liquid 30 g
Description: Clear, viscous liquid, colourless or pale brownish-yellow liquid syrup (solution). The products will be provided in sachets to be dissolved in 250 mL water.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glucose
Description: White crystalline powder. To standardise for 30 g glucose, 33 g glucose monohydrate will be used. The products will be provided in sachets to be dissolved in 250 mL water.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Still water
Description: 250 mL still water will be used. Water from the same source will be also used to dissolve investigational and control products
Study: NCT01040104

Intervention type: OTHER
Intervention: Blood taking
Description: Blood taking on day 90

Intervention type: OTHER
Intervention: Blood taking
Description: Blood taking on day 90
Study: NCT01835470

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abatacept
Study: NCT03853356

Intervention type: DEVICE
Intervention: Orthoss
Description: Orthoss® granules. Orthoss® granules mixed with local bone and pedicle bone marrow aspirate.
Study: NCT01040104

Intervention type: OTHER
Intervention: Blood taking
Description: Blood taking on day 90

Intervention type: OTHER
Intervention: Blood taking
Description: Blood taking on day 90

Intervention type: OTHER
Intervention: Blood taking
Description: Blood taking on day 90
Study: NCT03892772

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SAS0421a
Description: treatment will be given for 3 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAS0421a
Description: treatment will be given for 3 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SAS0421b
Description: treatment will be given for 3 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAS0421b
Description: treatment will be given for 3 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAS0421c
Description: treatment will be given for 3 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SAS0421c
Description: treatment will be given for 3 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo will be given for 3 days
Study: NCT02026700

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: bariederm cream
Description: patients are asked to apply twice a day a barrier cream on their hands for 3 weeks only
Study: NCT03861598

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carvedilol
Description: Carvedilol orally starting at 6.25 mg and increasing to 12.5 mg if tolerated after 1-2 weeks for a total of 4 cycles of treatment.
Study: NCT04271709

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Intervention Using Patient Navigators
Description: Enhanced support includes patient navigators to assist with all aspects of follow-up eye care and ocular surgery at either Harkness Eye Institute or Harlem Hospital, specifically eye exam appointment scheduling and arranging transportation over a 1-year period.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Usual Care
Description: Usual Care subjects who fail the screening and need vision correction will be given an eyeglasses prescription and a list of optical shops within 1 mile from their home. These subjects who are referred to an ophthalmologist for a follow-up eye exam will only be scheduled for their initial appointment at either Harkness Eye Institute or Harlem Hospital. They will not receive enhanced support. Scheduling this initial appointment will allow tracking of adherence.
Study: NCT01828242

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Empowerment model to improve dietary intake
Description: Empowerment model using specific guidelines to improve dietary intake

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control group following conventional approach
Description: Control group following conventional approach
Study: NCT01709019

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Low dose RSV-F Vaccine with Adjuvant (Day 0); Seasonal TIV (Day 0 & Day 28)
Description: 0.5mL IM injections

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Low dose RSV-F Vaccine without Adjuvant (Day 0); Seasonal TIV (Day 0 & day 28)
Description: 0.5mL IM injections

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: High dose RSV-F Vaccine with Adjuvant (Day 0); Seasonal TIV (Day 0 & Day 28)
Description: 0.5mL IM injections
Study: NCT04748809

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Diet 1
Description: Dietary intervention

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diet 2
Description: Dietary intervention
Study: NCT02528630

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Progressive resistance strength training program
Description: Patients undergo to strength training for intrinsic muscles of the hand twice a week, during 12 weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Joint protection and energy conservation advice
Description: A session regarding joint protection and energy conservation for hands was done before randomization.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Joint protection and energy conservation advice
Description: A session regarding joint protection and energy conservation for hands was done before randomization.
Study: NCT03680482

Intervention type: OTHER
Group type: OTHER
Intervention: Intervention ingest a 48 mg of sucralose
Description: Intervention: Subjects with type 2 diabetes who ingest a 48 mg of sucralose. Sucralose is a non-caloric sweetener derived from sucrose and is 600 times more sweet than sucrose. Your allowable daily intake is 15 mg / kg of body weight per day. 85% is not absorbed and is excreted unchanged in the stool; the rest that is absorbed is excreted unchanged by the urine

Intervention type: OTHER
Group type: OTHER
Intervention: Intervention ingest a 96 mg of stevia
Description: Intervention: Subjects with type 2 diabetes who ingest a 96 mg of stevia (steviol glycosides). The word stevia refers to the whole plant of Stevia rebaudiana Bertoni (SRB), only some of the components of the stevia leaf are sweet. Steviol glycosides are up to 300 times sweeter than sucrose, do not provide calories and can be used as a substitute for sucrose or as a non-nutritive sweetener alternative. Your allowable daily intake is 4 mg / kg / body weight (expressed as steviol)
Study: NCT00449930

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sitagliptin phosphate
Description: (1) sitagliptin 100mg tablet once daily (q.d.) for a 24-wk treatment period

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: metformin hydrochloride
Description: (4) Metformin 500mg tablets once daily (q.d.) for a 24-wk treatment period.
Study: NCT04810507

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anagliptin BID Treatment
Description: Continuous Glucose Monitoring with Anagliptin 100mg BID or Sitagliptin 100mg QD treatment for 12 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anagliptin BID Treatment
Description: Continuous Glucose Monitoring with Anagliptin 100mg BID or Sitagliptin 100mg QD treatment for 12 weeks
Study: NCT01664000

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: thioureidobutyronitrile
Description: Kevetrin (thioureidobutyronitrile)
Study: NCT00367679

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pazopanib
Description: Pazopanib is an oral, potent, multi-target receptor tyrosine kinase inhibitor of VEGFR-1, -2, -3, PDGFR-alpha and -beta and c-kit. Subjects were to receive 800 mg oral pazopanib daily for a minimum of 2 weeks to a maximum of 6 weeks.
Study: NCT03090919

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Platelet transfusion

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Study: NCT03402620

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gonadotropins
Description: Human menopausal gonadotropin 75 IU ampoules start at cycle day 2

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gonadotropins
Description: Human menopausal gonadotropin 75 IU ampoules start at cycle day 2
Study: NCT01669668

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: radiofrequency ablation
Description: Undergo RFA

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: laparoscopy
Description: Undergo laparoscopic ultrasound
Study: NCT03620773

Intervention type: DRUG
Group type: OTHER
Intervention: Aminohippurate Sodium Inj 20%
Description: Diagnostic aid/agent used to measure effective renal plasma flow (ERPF)
Study: NCT01709019

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: High dose RSV-F Vaccine without Adjuvant (Day 0); Seasonal TIV (Day 0 & Day 28)
Description: 0.5mL IM injections
Study: NCT03620773

Intervention type: DRUG
Group type: OTHER
Intervention: Iohexol Inj 300 mg/mL
Description: Diagnostic aid/agent used to measure glomerular filtration rate (GFR)

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Vertical Sleeve Gastrectomy
Description: Participants will undergo vertical sleeve gastrectomy surgery, a laparoscopic bariatric surgery procedure designed for weight loss in obese patients

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Renal Biopsy
Description: Minimally invasive outpatient procedure in interventional radiology to obtain renal tissue cores.
Study: NCT01709019

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Day 0 & Day 28); Seasonal TIV (Day 0)
Description: 0.5mL IM Injections